Charles Schwab Investment Management Inc. Has $21.46 Million Stock Position in Omnicell, Inc. $OMCL

Charles Schwab Investment Management Inc. reduced its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 0.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 613,758 shares of the company’s stock after selling 2,395 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.31% of Omnicell worth $21,457,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. increased its position in Omnicell by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 244,644 shares of the company’s stock valued at $8,553,000 after acquiring an additional 6,288 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Omnicell in the 1st quarter valued at approximately $2,073,000. Jane Street Group LLC increased its position in Omnicell by 7.4% in the 4th quarter. Jane Street Group LLC now owns 54,282 shares of the company’s stock valued at $2,417,000 after acquiring an additional 3,725 shares during the period. Invesco Ltd. increased its position in Omnicell by 2.4% in the 4th quarter. Invesco Ltd. now owns 219,453 shares of the company’s stock valued at $9,770,000 after acquiring an additional 5,063 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in Omnicell in the 1st quarter valued at approximately $901,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

OMCL has been the topic of a number of analyst reports. Wall Street Zen lowered shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 9th. Bank of America upped their price objective on shares of Omnicell from $30.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, May 23rd. Wells Fargo & Company upped their price objective on shares of Omnicell from $37.00 to $40.00 and gave the company an “overweight” rating in a research note on Monday, July 21st. Piper Sandler reduced their price objective on shares of Omnicell from $57.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 11th. Finally, Benchmark reduced their price objective on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Omnicell currently has a consensus rating of “Moderate Buy” and an average target price of $46.71.

Omnicell Stock Up 0.4%

Shares of NASDAQ OMCL opened at $31.89 on Friday. The firm has a market cap of $1.46 billion, a PE ratio of 63.78, a P/E/G ratio of 9.27 and a beta of 0.78. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.74. The company’s fifty day simple moving average is $29.53 and its 200 day simple moving average is $31.99. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.15. The business had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. Omnicell’s revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, sell-side analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.